CA2736441A1 - Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique - Google Patents

Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique Download PDF

Info

Publication number
CA2736441A1
CA2736441A1 CA2736441A CA2736441A CA2736441A1 CA 2736441 A1 CA2736441 A1 CA 2736441A1 CA 2736441 A CA2736441 A CA 2736441A CA 2736441 A CA2736441 A CA 2736441A CA 2736441 A1 CA2736441 A1 CA 2736441A1
Authority
CA
Canada
Prior art keywords
substituted
aryl
alkyl
cftr
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2736441A
Other languages
English (en)
Inventor
Alan S. Verkman
Mark J. Kurth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to CA2736441A priority Critical patent/CA2736441A1/fr
Publication of CA2736441A1 publication Critical patent/CA2736441A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2736441A 2011-04-06 2011-04-06 Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique Abandoned CA2736441A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2736441A CA2736441A1 (fr) 2011-04-06 2011-04-06 Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2736441A CA2736441A1 (fr) 2011-04-06 2011-04-06 Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique

Publications (1)

Publication Number Publication Date
CA2736441A1 true CA2736441A1 (fr) 2012-10-06

Family

ID=46964768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736441A Abandoned CA2736441A1 (fr) 2011-04-06 2011-04-06 Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique

Country Status (1)

Country Link
CA (1) CA2736441A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023367A1 (fr) 2012-08-09 2014-02-13 Phenex Pharmaceuticals Ag Hétérocycles à 5 chaînons contenant de l'azote substitués par carboxamide ou sulfonamide en tant que modulateurs pour le récepteur nucléaire orphelin ror gamma
WO2015196071A1 (fr) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
WO2015197187A1 (fr) * 2014-06-24 2015-12-30 Grünenthal GmbH Carboxamides à base de pyrazolyle v
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392372B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10550106B2 (en) 2015-10-06 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023367A1 (fr) 2012-08-09 2014-02-13 Phenex Pharmaceuticals Ag Hétérocycles à 5 chaînons contenant de l'azote substitués par carboxamide ou sulfonamide en tant que modulateurs pour le récepteur nucléaire orphelin ror gamma
US9458104B2 (en) 2012-08-09 2016-10-04 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ
EP3118189A1 (fr) 2012-08-09 2017-01-18 Phenex Pharmaceuticals AG Azote substitue de carboxamide ou sulfonamide contenant des heterocycles a 5 chainons en tant que modulateurs de recepteur nucleaire orphelin gamma ror
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US10017503B2 (en) 2014-03-13 2018-07-10 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015196071A1 (fr) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
US10174014B2 (en) 2014-06-19 2019-01-08 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US10738040B2 (en) 2014-06-19 2020-08-11 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015197187A1 (fr) * 2014-06-24 2015-12-30 Grünenthal GmbH Carboxamides à base de pyrazolyle v
US10392372B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US11098035B2 (en) 2014-12-23 2021-08-24 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
RU2767460C2 (ru) * 2014-12-23 2022-03-17 Протеостазис Терапьютикс, Инк. Соединения, композиции и способы для повышения активности cftr
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
US11083709B2 (en) 2015-07-24 2021-08-10 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
US10550106B2 (en) 2015-10-06 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US11136313B2 (en) 2015-10-06 2021-10-05 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US11248010B2 (en) 2016-04-07 2022-02-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity

Similar Documents

Publication Publication Date Title
CA2736441A1 (fr) Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique
US8143295B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
US8389736B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
US7939558B2 (en) Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
JP4880671B2 (ja) １Ｈ−ピラゾール４−カルボキシルアミドその製造方法および１１β−ヒドロキシステロイドデヒドロゲナーゼとしてのその使用
US20120196854A1 (en) Pharmaceutical composition comprising aromatic heterocyclic compound
US6492425B1 (en) Inhibitors of transcription factor-NF-κB
EA028918B1 (ru) Производные 5-аминотетрагидрохинолин-2-карбоновых кислот и их применение в качестве активатора растворимой гуанилатциклазы
JP2007504127A (ja) 好中球エラスターゼ阻害剤としてのキノキサリン誘導体およびその使用
EP1660452A1 (fr) Derives de quinoline utilises comme inhibiteurs de l'elastase neutrophile et utilisation de ces derives
JP2002512957A (ja) Ｃｃｒ−３受容体アンタゴニスト
WO2009051910A1 (fr) Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations
JP2002512960A (ja) Ｃｃｒ−３受容体アンタゴニスト
JP2017501164A (ja) 置換されたピペリジニルテトラヒドロキノリン類
CA2335293A1 (fr) Inhibiteurs du facteur de transcription nf-.kappa.b
JP2022527980A (ja) 新規化合物およびこれを有効成分として含む呼吸器疾患の予防または治療用組成物
US9073863B2 (en) Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
WO2012166654A1 (fr) Composés de cyanoquinoléine ayant une activité pour corriger le traitement de la protéine cftr mutante et augmenter le transport ionique et les utilisations de ceux-ci
CN115947716A (zh) 一种靶向Nur77的吲哚衍生物及其应用
MXPA00012498A (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-&kgr;B
MXPA00012499A (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-&kgr;B

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20140408